Loading page…

Astal Laboratories Ltd (ASTALLTD) · mywealthgrid

About

Astal Laboratories Ltd is registered in pharmaceuticals but operates at negligible scale — the largest reported quarterly revenue is ₹0.05 Cr (Mar 2021), with most periods showing n/a. The company occupies the healthcare sector within India's pharma industry but its product portfolio, manufacturing capacity, and market positioning remain unclear from available metrics.

Face value: ₹10

Market cap

₹305 Cr

P/E

—

P/B

0.9×

Dividend yield

ROE

4.5%

ROCE

6.7%

Debt / equity

0.04

OPM

8.2%

EPS (TTM)

₹0.0

Book value

₹77.5

52-week high

₹100.6

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Revenue base is negligible (₹0.05 Cr at most; most quarters n/a), making profitability and margin figures unreliable as guides to sustainable operations.
Promoter holding has fallen to 4.53% (Jun 2026), signaling heavy founder exit — verify whether this reflects strategic dilution, funding events, or loss of confidence in the business model.
Institutional backing is zero (FII 0%, DII 0%), concentrating 95.47% of shares with retail public holders and eliminating large informed shareholders to anchor valuation or monitor management.
Stock has fallen 12.36% over 1y despite reported ROE of 30.1% — verify whether recent results (2026-08-14) and the latest filing (2026-07-09) explain the market's disconnect.

Generated analysis · source review pending

Growth drivers

ROE of 30.1% suggests the company deploys capital efficiently on what revenue exists; verify whether pipeline products or market opportunities can justify scaling this metric.
Operating margin of 19.88% indicates cost discipline or lean operations; verify whether this margin holds as the company scales revenue and whether it reflects a sustainable business model or low current overhead.
Low debt (D/E 0.37) leaves balance-sheet capacity to fund manufacturing capacity, R&D, or market entry — verify what capex or expansion the company plans.

Generated analysis · source review pending

₹69.5-18.1%1Y

Beta

0.62

Damps index moves

Volatility (1y)

51.4%

Annualised, daily returns

RSI (14)

28.6

Oversold territory

Rel. strength (1y)

-28%

Behind the market

Beta is measured against NIFTY 50 over three years of weekly returns — 1 moves with the index, above 1 amplifies it, below 1 damps it.

Quick read

rule-based

Pros

+Profit CAGR of 281.9% over the last 5 years
+Revenue CAGR of 278.8% over the last 5 years
+Almost debt-free (debt/equity 0)

Cons

−Low promoter holding of 4.5%
−Promoter holding fell 15.4 pts over the last year

Research score

Structured signal from quality, growth, valuation and momentum.

48/100

Business quality: 34
Growth: 100
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	—	—	—	—	—	0	0	4	24	64	156
COGS	—	—	—	—	—	0	0	3	21	48	139
Gross profit	—	—	—	—	—	—	—	0	2	16	17
	—	—	—	—	—	0	0	0	1	3	4
	—	—	—	—	—	0	-0	0	1	13	13
OPM %	—	—	—	—	—	15%	-4.8%	1.4%	4.7%	19.9%	8.2%
Depreciation	—	—	—	0	0	0	0	0	0	0	1
Interest	—	—	—	—	—	0	0	0	0	1	1
	0	0	0	0	0	0	0	0	0	0	0
Profit before tax	0	0	0	-0	-0	0	-0	0	1	12	11
Tax	0	0	0	0	0	0	0	0	0	3	3
Tax %	0%	0%	—	0%	0%	0%	0%	66.7%	27.5%	25.5%	25.3%
	0	0	-0	-0	-0	0	-0	0	1	9	8
PAT margin %	—	—	—	—	—	5%	-9.5%	0.6%	3.3%	13.9%	5.2%
EPS (₹)	—	0	—	-0.2	-0.1	0	-0	0	1.6	9.1	4.8
EPS adjusted (₹)	—	—	—	—	-0.1	0	-0.1	0.1	0.8	9.1	1.9
Annual report	Annual report for Mar 2016	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	4	4	4	4	10	10	42
Reserves	—	1	1	1	13	26	285
	—	0	0	0	0	13	12
	—	0	0	5	13	14	60
Total equity & liabilities	—	5	5	10	37	63	400
	0	0	0	0	1	11	11
CWIP	—	0	0	0	0	0	0
Investments	—	0	0	0	0	0	277
	—	5	5	10	36	52	111
Total assets	—	5	5	10	37	63	400

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	—	—	7.2%	9.8%	25.1%	11%
EBITDA margin %	—	—	15%	-4.8%	1.4%	4.7%	19.9%	8.2%
EBIT margin %	—	—	5%	-9.5%	1.1%	4.6%	19.5%	7.8%
PAT margin %	—	—	5%	-9.5%	0.6%	3.3%	13.9%	5.2%
Working capital
Receivable days	—	—	0	0	321	244	157	169
Inventory days	—	—	0	0	0	18	112	76
Payable days	—	—	0	0	413	197	82	142
NWC days	—	—	0	0	-92	65	187	103
Leverage
Current ratio	—	—	39.85	1.43	1.29	2.05	1.78	1.45
Debt to EBITDA	—	—	0	—	0	0.28	1.04	0.94
Debt to equity	—	—	0	0	0	0.01	0.37	0.04
Interest coverage	—	—	—	—	—	110	18.1	8.7
Asset turnover	—	—	0.04	0.04	0.36	0.65	1.01	0.39
Return ratios
Return on assets %	—	—	0.2%	-0.4%	0.2%	2.1%	14.1%	2%
Return on capital employed %	—	—	0.2%	-0.4%	0.8%	7.6%	42.1%	6.7%
Return on equity %	—	—	0.2%	-0.4%	0.4%	3.3%	24.8%	2.5%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	55.72%	39.79%	19.93%	19.93%	19.93%	19.93%	19.93%	19.93%	18.19%	18.19%	4.7%	4.53%
FII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
DII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	44.28%	60.21%	80.07%	80.07%	80.07%	80.07%	80.07%	80.07%	81.81%	81.81%	95.3%	95.47%
No. of shareholders	—	—	—	—	—	—	—	—	2,899	2,926	3,065	3,274

Promoter holding down 51.19 percentage points since Sep 2023.

9 deals · 25 Jan 2022 – 18 Oct 2024

Date	Client	Type	Venue	Side	Quantity	Price	Value
18 Oct 2024	GANESH KUMAR	Bulk	BSE	Buy	54,000	₹90.45	₹0.49 Cr
4 Sept 2023	KANTA DEVI SAMDARIA	Bulk	BSE	Buy	24,712	₹32.05	₹0.08 Cr
29 Aug 2023	ALPA KAMLESH SHAH	Bulk	BSE	Sell	46,000	₹30.53	₹0.14 Cr
29 Aug 2023	JAINAM UDAY SHAH	Bulk	BSE	Buy	27,001	₹30.53	₹0.08 Cr
8 May 2023	KALYAN CHAKRAVARTHY MUPPARAJU	Bulk	BSE	Sell	21,000	₹32.62	₹0.07 Cr
15 Feb 2022	KAMLESH NATWARLAL SHAH	Bulk	BSE	Buy	20,576	₹10.24	₹0.02 Cr
27 Jan 2022	RAMCHANDRA PANDHAREE PAL	Bulk	BSE	Sell	32,500	₹8.45	₹0.03 Cr
27 Jan 2022	RAJKUMAR RAMPRASAD PAL	Bulk	BSE	Sell	31,779	₹8.45	₹0.03 Cr
25 Jan 2022	SHRUTI YASHWANTBIHARI KAGZI	Bulk	BSE	Sell	20,350	₹8.64	₹0.02 Cr

1–9 of 9

1 / 1

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Mr. SUDHEER KARNA KANKANALAExecutive Director
Mrs. RAVIKANTI SHAILAJANon-Executive - Non Independent Director
Mr. MAGGIDI VENKATESHNon-Executive - Non Independent Director
Mrs. HEMACHAKRAPANI BANGARAIAHGARINon-Executive - Independent Director
Mr. RADHAKISHORE PANDRANGINon-Executive - Independent Director
Mr. BIRENDRAKUMAR SAHOONon-Executive - Independent Director
Mr. JULIUS PAUL REINHARD PASCHKENon-Executive - Independent Director
Mr. Balayogiswara Rao PeddintiChief Financial Officer
Mr. Mahendra KumarCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Astal Laboratories Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Board meeting to consider results14 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

21 announcementsExport CSV

30 Sept 2026, 7:15 pmAGM/EGM

Shareholders Meeting- Voting Results Of 33Rd AGM

AGM PDF

30 Sept 2026, 7:11 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

AGM PDF

30 Sept 2026, 2:06 pmInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

30 Sept 2026, 12:18 pmCompany Update

Announcement Under Regulation 30 (LODR)- Appointment Of Cost Auditor, Secretarial Auditor And Internal Auditor On Material Subsidiary Of The Company.

General PDF

30 Sept 2026, 12:16 pmCompany Update

Announcement Under Regulation 30 (LODR)- Appointment Of Company Secretary In Material Wholly Owned Subsidary.

General PDF

29 Sept 2026, 6:01 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

AGM PDF

11 Sept 2026, 3:11 pmCompany Update

Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015

Code of Conduct under SEBI (PIT) Regulations, 2015 PDF

9 Sept 2026, 7:39 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

Date	Category	Subject	Filing
30 Sept 2026, 7:15 pm	AGM/EGM AGM	Shareholders Meeting- Voting Results Of 33Rd AGM	PDF
30 Sept 2026, 7:11 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report	PDF

Loading announcements…

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	0	-0	-1	-6	-13	-3
	0	0	0	-6	-8	-1
	0	0	1	18	3	5
Net cash flow	0	-0	0	6	-17	0
Free cash flow	0	-0	-1	-6	-18	-3
CFO / Operating profit %	66.7%	—	—	-498.2%	-98%	-24.1%

Astal Laboratories Ltd

Astal Laboratories Ltd

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

1

Announcements

1

Not in the F&O segment

No fund holdings on record

Announcements

Annual reports

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

Astal Laboratories Ltd

Astal Laboratories Ltd

About

Key insights

Key risks

Growth drivers

Risk & technicals

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

Board meetings1

Announcements

Board meetings1

Ratio timeline

Quarterly record

Bulk & block deals

Board and management

Not in the F&O segment

No fund holdings on record

Announcements

Annual reports

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

1

1